Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Summary - Thomson StreetEvents

Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Summary

Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Summary - Thomson StreetEvents
Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Summary
Published Dec 17, 2021
Published Dec 17, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of PFE.N conference call or presentation 17-Dec-21 1:30pm GMT

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Pfizer Inc
Ticker
PFE.N
Time
1:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : A couple for me. First, regarding PAXLOVID manufacturing, I understand that one of the gating factors to increasing capacity is the time for API production. And just -- could you talk about this and what work you're doing regarding optimizing this time to give yourselves a greater flexibility in the future? And then second question is, I understand you have an IV protease inhibitor in development. Could you just give us a little more color on that and when we should expect to see data from the program?

Table Of Contents

Pfizer Inc Q4 2021 Earnings Call Summary – 2022-02-08 – US$ 54.00 – Edited Brief of PFE.N earnings conference call or presentation 8-Feb-22 3:00pm GMT

Pfizer Inc to Discuss Board Oversight of ESG- Fireside Chat Transcript – 2022-02-01 – US$ 54.00 – Edited Transcript of PFE.N conference call or presentation 1-Feb-22 3:00pm GMT

Pfizer Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-10 – US$ 54.00 – Edited Transcript of PFE.N presentation 10-Jan-22 8:00pm GMT

Pfizer Inc at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript – 2022-01-06 – US$ 54.00 – Edited Transcript of PFE.N presentation 6-Jan-22 3:00pm GMT

Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Transcript – 2021-12-17 – US$ 54.00 – Edited Transcript of PFE.N conference call or presentation 17-Dec-21 1:30pm GMT

Pfizer Inc To Acquire Arena Pharmaceuticals Inc - M&A Call Summary – 2021-12-13 – US$ 54.00 – Edited Brief of PFE.N M&A conference call or presentation 13-Dec-21 3:00pm GMT

Pfizer Inc To Acquire Arena Pharmaceuticals Inc - M&A Call Transcript – 2021-12-13 – US$ 54.00 – Edited Transcript of PFE.N M&A conference call or presentation 13-Dec-21 3:00pm GMT

Pfizer Inc to Discuss Updated Phase 1 Dose Escalation Data for ARV-471 Call Summary – 2021-12-10 – US$ 54.00 – Edited Brief of PFE.N conference call or presentation 10-Dec-21 1:30pm GMT

Pfizer Inc to Discuss Updated Phase 1 Dose Escalation Data for ARV-471 Call Transcript – 2021-12-10 – US$ 54.00 – Edited Transcript of PFE.N conference call or presentation 10-Dec-21 1:30pm GMT

Pfizer Inc at Evercore ISI HealthCONx Virtual Conference Transcript – 2021-12-01 – US$ 54.00 – Edited Transcript of PFE.N presentation 1-Dec-21 10:10pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Summary" Dec 17, 2021. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Pfizer-Inc-Analyst-and-Investor-Call-to-Discuss-Pfizer-BioNTech-COVID-19-Vaccine-and-Pfizer-s-Novel-COVID-19-Oral-Antiviral-Treatment-Candidate-B15068474>
  
APA:
Thomson StreetEvents. (2021). Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Summary Dec 17, 2021. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Pfizer-Inc-Analyst-and-Investor-Call-to-Discuss-Pfizer-BioNTech-COVID-19-Vaccine-and-Pfizer-s-Novel-COVID-19-Oral-Antiviral-Treatment-Candidate-B15068474>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.